二尖瓣位置生物瓣膜的长期结局:过去20年发表研究的系统综述
该系统综述检索了报告二尖瓣生物瓣膜置换术后至少5年随访结局的研究,共纳入21项研究、15833例患者。10年免于结构瓣膜衰败率为58.9%至100%,15年为58.3%至93%;10年免于再手术率为65%至98.7%,15年为78.5%至91%。作者认为报告异质性大,难以得出无偏、可推广的结论。
要点
- 二尖瓣生物瓣膜置换术后10年免于结构瓣膜衰败率为58.9%至100%,15年为58.3%至93%。
- 10年免于再手术率为65%至98.7%,15年为78.5%至91%。
- 25%和66%的研究分别缺失自体瓣膜病理或主导血流动力学病变信息。
核心结论
- 二尖瓣生物瓣膜置换长期结局的报告存在相当大的变异性。
- 因此难以在二尖瓣疾病全谱系中生成无偏、可推广的长期结局理解。
研究设计与样本
- 系统综述,检索Medline、Embase和Cochrane CENTRAL数据库中报告二尖瓣生物瓣膜置换术后至少5年随访结局的研究。
- 共纳入21项研究、15833例患者。
- 使用Cochrane QUIPS工具评估纳入研究的偏倚风险。
主要发现
- 所有植入瓣膜中64%为猪瓣,其余为牛心包瓣。
- 10年免于结构瓣膜衰败率为58.9%至100%,15年为58.3%至93%。
- 10年免于再手术率为65%至98.7%,15年为78.5%至91%。
- 25%的研究缺失自体瓣膜病理信息,66%的研究缺失主导血流动力学病变信息。
- 尽管结构瓣膜衰败诊断高度依赖超声心动图,但术后超声心动图报告缺乏。
关键数值与推荐
- 10年免于结构瓣膜衰败率为58.9%至100%。
- 15年免于结构瓣膜衰败率为58.3%至93%。
- 10年免于再手术率为65%至98.7%。
- 15年免于再手术率为78.5%至91%。
局限性
- 25%的研究缺失自体瓣膜病理信息,66%的研究缺失主导血流动力学病变信息。
- 术后超声心动图报告缺乏,尽管结构瓣膜衰败诊断高度依赖超声心动图。
- 二尖瓣生物瓣膜置换长期结局的报告存在相当大的变异性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Although the use of bioprostheses for mitral valve replacement (bMVR) is on the rise, their long-term durability is not well described. Defining bMVR durability will be instrumental in setting the standard against which the performance of transcatheter mitral replacement is to be judged against. The authors of this systematic review aimed to identify, assess the quality and review the outcomes in studies reporting on long-term outcomes after bMVR published over the last 20 years. METHODS: Medline, Embase and Cochrane CENTRAL were searched for studies that have reported outcomes beyond a minimum of 5 years of follow-up after bMVR. Cohort characteristics, definitions of structural valve deterioration (SVD) and outcomes were summarized. The risk of bias in included studies was assessed using the Cochrane QUIPS tool. RESULTS: Twenty-one studies, including 15 833 patients, were identified. Sixty-four percent of all implants were porcine and the remaining bovine pericardial. Freedom from SVD at 10 years ranged from 58.9% to 100% and at 15 years from 58.3% to 93%. Freedom from reoperation ranged from 65% to 98.7% at 10 years and 78.5% to 91% at 15 years. Information on native valve pathology or dominant haemodynamic lesion was missing in 25% and 66% of studies, respectively. Reports of postoperative echocardiography were lacking, despite the heavy reliance on echocardiography for SVD diagnosis. CONCLUSIONS: There is considerable variability in reporting bMVR long-term outcomes. As such, it is difficult to generate an unbiased, generalizable understanding of long- term outcomes after bMVR across the spectrum of mitral disease phenotypes.
引用
- Koulouroudias M, Di Mauro M, Lorusso R, et al. Long-term outcomes of bioprosthetic valves in the mitral position a systematic review of studies published over the last 20 years. Eur J Cardiothorac Surg. 2023. PMID: 37963023. doi:10.1093/ejcts/ezad384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。